Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Cash and Equivalents of $198.69 million for fiscal year 2025.
MADRIGAL PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $198.69M | +98.7% |
| 2024 | $100.02M | +0.1% |
| 2023 | $99.92M | -69.9% |
| 2022 | $331.55M | +814.1% |
| 2021 | $36.27M | -32.8% |
| 2020 | $54.00M | +15.6% |
| 2019 | $46.70M | -18.6% |
| 2018 | $57.38M | -61.4% |
| 2017 | $148.63M | +676.3% |
| 2016 | $19.14M | +6156.5% |
| 2015 | $306.0K | +106.7% |
| 2014 | $148.1K | -99.7% |
| 2013 | $48.49M | -40.5% |
| 2012 | $81.51M | +171.0% |
| 2011 | $30.07M | -3.9% |
| 2010 | $31.31M | -29.1% |
| 2009 | $44.16M | -15.2% |
| 2008 | $52.05M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $295.69M | +27.1% | +58.8% |
| June 30, 2025 | $186.19M | -62.4% | +1.4% |
| March 31, 2025 | $183.65M | -70.5% | +83.6% |
| December 31, 2024 | $100.02M | +0.1% | -57.0% |
| September 30, 2024 | $232.68M | +275.0% | -53.0% |
| June 30, 2024 | $494.60M | +540.7% | -20.5% |
| March 31, 2024 | $622.52M | +449.4% | +523.0% |
| December 31, 2023 | $99.92M | -69.9% | +61.0% |
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +98.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, MADRIGAL PHARMACEUTICALS, INC.’s cash and equivalents has grown by 281.8% (from $52.05 million to $198.69 million).
- The most recent figure is from MADRIGAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: